896127-80-3

Basic information

• Product Name: 5-Chloro-2-methoxybenzenemethanamine
• Synonyms: 5-Chloro-2-methoxybenzenemethanamine;(4-chloro-2-Methoxyphenyl)MethanaMine;4-Chloro-2-methoxy-benzenemethanamine;4-Chloro-2-methoxybenzylamine
• CAS NO: 896127-80-3
• Molecular Formula: C8H10ClNO
• Molecular Weight: 171.62
• Mol File: 896127-80-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 252.785 °C at 760 mmHg
• Flash Point: 106.681 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: 5-Chloro-2-methoxybenzenemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-methoxybenzenemethanamine(896127-80-3)
• EPA Substance Registry System: 5-Chloro-2-methoxybenzenemethanamine(896127-80-3)

Safety Data

• Hazardous Substances Data: 896127-80-3(Hazardous Substances Data)

Usage

General Description

5-Chloro-2-methoxybenzenemethanamine is a complex organic compound that includes multiple functional groups such as a chloro group, a methoxy group, and an amine group. Scientifically, it is classified under aryl halides and primary amines. It incorporates a unique chemical structure which consists of a benzene ring substituted with a 5-chloro, a 2-methoxy, and a methanamine group. 5-Chloro-2-methoxybenzenemethanamine is worth noting for its integral role in numerous chemical reactions, making it a valuable substance in organic chemistry, notably in the pharmaceutical and chemical industries. Despite the complex nature of its name, this chemical is essential to broad scientific applications and chemical synthesis.

InChI:InChI=1/C8H10ClNO/c1-11-8-3-2-7(9)4-6(8)5-10/h2-4H,5,10H2,1H3

Upstream product

• 101079-84-9 4-chloro-1-(chloromethyl)-2-methoxybenzene 
• 78955-90-5 methyl 4-chloro-2-methoxybenzoate 
• 90296-27-8 (4-chloro-2-methoxy-phenyl)methanol 
• 896127-79-0 1-(azidomethyl)-4-chloro-2-methoxybenzene 

Relevant articles and documents

SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES

The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY

Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.